Ionis Pharmaceuticals, Inc.(IONS)Earnings, Financials & Key RatiosIonis Pharmaceuticals, Inc. (IONS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's narrowing liquidity buffer, with cash and equivalents falling to $173.4M in 2026Q1, suggests substantial risk of future dilution to support ongoing operations.
Ionis Pharmaceuticals, Inc. (IONS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Ionis Pharmaceuticals, Inc. (IONS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.56vs $0.85+34.1% | $246Mvs $196M+25.8% |
| Q1 2026 | Feb 25, 2026 | $1.41vs $1.24-14.0% | $203Mvs $156M+30.1% |
| Q4 2025 | Oct 29, 2025 | $0.61vs $1.15+47.0% | $157Mvs $154M+2.1% |
| Q3 2025 | Jul 30, 2025 | $0.86vs $0.27+218.5% | $452Mvs $132M+243.1% |
Recent stock market news and headlines for Ionis Pharmaceuticals, Inc. (IONS)
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an investigational RNA-targeted medicine for people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder associated with significant impairments in communication, physical function and cognition. The pivotal cohort enrolled 136 participants.
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.
Key metrics vs top competitors for Ionis Pharmaceuticals, Inc. (IONS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $86.33 | $14.27B | -36.27 | 33.87% | -40.36% | -70.72% | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $60.35 | $11.61B | 33.53 | 12.87% | 8.29% | 4.41% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — |
Ionis Pharmaceuticals, Inc. (IONS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Ionis Pharmaceuticals, Inc. (IONS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 29, 2026·SEC
Apr 21, 2026·SEC
Mar 9, 2026·SEC
Get notified when IONS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ionis Pharmaceuticals, Inc. (IONS) stock FAQ — growth, dividends, profitability & financials explained
Ionis Pharmaceuticals, Inc. (IONS) reported $1.06B in revenue for fiscal year 2025. This represents a 4560% increase from $22.7M in 1996.
Ionis Pharmaceuticals, Inc. (IONS) grew revenue by 33.9% over the past year. This is strong growth.
Ionis Pharmaceuticals, Inc. (IONS) reported a net loss of $326.6M for fiscal year 2025.
Ionis Pharmaceuticals, Inc. (IONS) has a return on equity (ROE) of -70.7%. Negative ROE indicates the company is unprofitable.
Ionis Pharmaceuticals, Inc. (IONS) had negative free cash flow of $971.3M in fiscal year 2025, likely due to heavy capital investments.
